News - Geron Corp

Filter

Current filters:

Geron Corp

Popular Filters

Geron nosedives on FDA clinical hold for blood disorders drug imetelstat

Geron nosedives on FDA clinical hold for blood disorders drug imetelstat

12-03-2014

USA-based Geron Corp saw its shares plunge 59% to $1.79 when the company revealed that it had received…

BiotechnologyGeron CorpimetelstatNorth AmericaOncologyRegulationResearchUSA

Geron’s stock price jumps as it reports positive results for myelofibrosis drug

Geron’s stock price jumps as it reports positive results for myelofibrosis drug

08-11-2013

Geron Corp (Nasdaq: GERN) has boosted its share price with the results of a clinical trial into the safety…

FinancialGeron CorpimetelstatNorth AmericaOncologyPharmaceuticalResearchUSA

Geron discontinues GRN1005 to concentrate on imetelstat; will cut jobs

05-12-2012

California, USA-based Geron Corp (Nasdaq: GERN), which scrapped its stem cell business a year ago to…

BiotechnologyFinancialGeron CorpGRN1005imetelstatOncologyResearch

Geron signs tentative deal with BioTime on stem cell assets

18-11-2012

A year after announcing its decision to exit stem cell therapy, the USA's Geron Corp (Nasdaq: GERN) has…

BiotechnologyBioTimeFinancialGeron CorpMergers & Acquisitions

Geron slumps as imetelstat fails in Ph II breast cancer and NSCLC studies

11-09-2012

Shares of US drug developer Geron Corp (Nasdaq: GERN) plunged 50% to $1.44 in pre-market trading yesterday,…

Geron CorpimetelstatOncologyPharmaceuticalResearch

Back to top